InfuSystem Hits Record Revenue as It Pivots to Higher-Margin Wound Care
The medical device rental specialist rides a 154% surge in compression therapy and a re-platformed ERP, while the GE restructuring clears room for durable growth.
INFU · Earnings Call · 2026-08-04
A Re-Platformed Pivot
InfuSystem has been quietly transforming its revenue mix. The second quarter of fiscal 2026 brought record revenue of $36.9 million, a 2.6% GAAP gain or 7.5% pro forma — but the more important story is what is driving that growth. The Compression devices line within Wound Care grew 154% year-over-year, adding $2.1 million and representing nearly 90% of the segment's increase. That came on top of the Oncology business, which crossed the $20 million quarterly threshold for the first time, up 6.4%. CEO Carrie Lachance was direct about the driver in the Q&A:
“That's really the key. If you have a really good partner that's going to get you all of the paperwork and work with their patients and their clinics to make sure that you have what you need is perfect.” — Carrie Lachance, Chief Executive Officer · 2026-08-04
That is a far cry from the company's earlier failed foray into compression therapy. As Lachance noted on the May call, “The difference today is really our partnerships.” — Carrie Lachance, Chief Executive Officer · 2026-05-07 The two manufacturing partners now on board cover both Pneumatic Compression Devices (PCDs) and the newer Adjustable Compression Wraps, which are easier for patients with limited mobility. The market-wide tailwind is the Lymphedema Treatment Act passed in 2024, which has helped reimbursement and patient access.
The new ERP is the other pillar of the transformation. Launched in March, it is already driving down costs and improving efficiency. CFO Barry Steele said on the call: “It was about half. They were about $600,000, $700,000 last year, and we're in the $300,000 range this quarter.” — Barry Steele, Chief Financial Officer · 2026-08-04 The system is not just a cost cut — it is an enabler for scaling the higher-touch Patient Services businesses without proportionally expanding back-office headcount.
What I would say is there's not any specific thing, but there's a lot of points of light... everything from managing working capital better to provide better cash flow as we grow to making push our throughput of devices and turning around devices to help us our utilization of devices.
The company's new ERP is expected to taper from ~$300k/quarter to near zero as the stabilization phase ends, while the longer-term benefits in pump turnaround and working capital should show up in the numbers next year.
The Wound Care Flywheel
The strategic pivot is visible in the segment mix. Patient Services revenue rose 15.2% to $24.8 million, while Device Solutions revenue fell 16.1% on the planned GE Healthcare contract restructuring and a one-time buyout in equipment sales. Yet Device Solutions gross profit held at $6.1 million, with gross margin jumping 8.3 points to 50.2%. The GE deal was consciously renegotiated to less revenue but much better economics.
“This restructuring improves our earnings because it allowed for an even larger reduction in direct contract expenses.” — Carrie Lachance, Chief Executive Officer · 2026-08-04
That discipline shows up in the bottom line. Adjusted EBITDA rose 7.6% to $8.6 million, and the margin expanded to 23.4%. Net income more than doubled to $3.2 million from $2.6 million a year ago. The company's Wound Care revenue is still small but growing quickly enough to move the needle.
Analysts asked repeatedly about sustainability — will the 154% growth hold? Lachance responded: “We continue to see volume coming in. That is improving, and we continue to foresee that happening through the remainder of 2026 and certainly beyond.” — Carrie Lachance, Chief Executive Officer · 2026-08-04
The company is also broadening its reimbursement moat. It now has more than 800 payer contracts covering 97% of U.S. insured lives, and Medicare exposure is below 10%. That is a very defensible foundation for a company that is still only $205 million by market cap.
Financial Discipline and the Bottom Line
The financial context fully supports management's narrative. The latest filed 10-Q shows gross margin of 58.4%, up more than 3 points year-over-year — a clear confirmation of the mix shift. Operating income was up 157% y/y, albeit off a small base. Free cash flow was negative in the most recent quarter due to rental equipment purchases, but operating cash flow for the first half was $7.7 million and the company holds $55.2 million in available liquidity.
The balance sheet is unusually conservative for a company growing at this clip. Net debt is just $19.5 million, or 0.61x trailing adjusted EBITDA. This gives management ample room to make tuck-in acquisitions or continue buying back stock, which they did to the tune of $4.4 million in the half.
The market has already taken notice. The stock is up more than 30% over the past 90 trading days, and the full-history tape shows a series of strong uptrends since 2020. The recent breakout looks like a vote of confidence in the Patient services pivot.
What Changed and Why It Matters
Before this quarter, the company was largely an oncology pump renter with a struggling wound care line and an expensive ERP project hanging over margins. Now it has a structurally better revenue mix, a self-funding growth engine in compression therapy, and the operational systems to scale it profitably.
The GE restructuring, painful on the top line, was the catalyst that forced a more disciplined approach to capital allocation. Management has explicitly prioritized return on invested capital over raw revenue growth — a message that resonates for a small-cap that has historically traded at a discount to its larger medtech peers.
While the growth is still small in absolute terms, the trajectory is unmistakable. The combination of a new ERP, strong payer coverage, and a supportive legislative tailwind gives InfuSystem an unusually clear runway for a company of its size. The 154% growth in compression devices is not just a one-off — it is a direct result of the partnerships and process improvements management has been building toward for over a year. As the company moves toward its 22–25% adjusted EBITDA margin target, the market is right to pay attention.